Next Article in Journal
Differences between Obese and Non-Obese Children and Adolescents Regarding Their Oral Status and Blood Markers of Kidney Diseases
Next Article in Special Issue
Mindfulness-Based Stress Reduction for Systemic Lupus Erythematosus: A Mixed-Methods Pilot Randomized Controlled Trial of an Adapted Protocol
Previous Article in Journal
Markers of Inflammation and Vascular Parameters in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids
Previous Article in Special Issue
Assessment of EULAR/ACR-2019, SLICC-2012 and ACR-1997 Classification Criteria in SLE with Longstanding Disease
 
 
Article
Peer-Review Record

Cytomegalovirus-Associated Autoantibody against TAF9 Protein in Patients with Systemic Lupus Erythematosus

J. Clin. Med. 2021, 10(16), 3722; https://doi.org/10.3390/jcm10163722
by Yen-Fu Chen 1,†, Ao-Ho Hsieh 1,†, Lian-Chin Wang 1, Kuang-Hui Yu 1,* and Chang-Fu Kuo 1,2,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
J. Clin. Med. 2021, 10(16), 3722; https://doi.org/10.3390/jcm10163722
Submission received: 27 July 2021 / Revised: 16 August 2021 / Accepted: 18 August 2021 / Published: 21 August 2021
(This article belongs to the Special Issue Systemic Lupus Erythematosus: Pathogenesis, Diagnosis and Treatment)

Round 1

Reviewer 1 Report

The authors give a follow-up of previous observations about the presence of anti-CMV cross-reacting autoantibodies in different rheumatic diseases with emphasis on SLE.

Methodology : the authors compare the results of purified anti-CMV65pp IgG with dsDNA and anti-TAF9 autoantibodies. They however do not mention how they purified the IgG. This must be added in the methodology section.

In Table 2, the 193 SLE patients are reduced to 163 in the anti-CMV65pp results. What happened to the 30 patients who disappeared?

Overall, the english is at the border of uncomprehensibility. The text should be rewritten by an english ediitor.

Author Response

Dear reviewer 

Please see the attachment

 

Sincerely

Ao-Ho Hsieh

Author Response File: Author Response.pdf

Reviewer 2 Report

While the manuscript is well written, I would like to clarify some points before we can accept their conclusions .  

Methods: Concerning the timeframe of the antibody determination, when were these antibodies tested? At the onset? At the same time? During the follow-up? (if so, when?)

The authors tested CMV IgG avidity but data are not shown in the Results section. 
Discussion:   One limitation of the study is that CMV reactivation can only be established by viral load (PCR) testing, as the authors already acknowledge in the manuscript. On the other hand. ELISA is a helpful tool to detect the presence of these antibodies but their pathogenic role remains uncertain (i.e. as TAF9 is a transcription factor EMSA testing may elucidate if DNA binding is impaired or not)a and CMV, as CMV may cause anemia throughout myelopoiesis interference (a central mechanism) while haemolytic anemia is driven by peripheral mechanism. In addition TAF9 is required for optimal B-globin expression Sengupta et al (PNAS 2009)  (DOI: 10.1073/pnas.0808347106, which reflects an alternative cause for anemia in the context of autoantibody production, The rationale to establish the link with this study is difficult to justify and I would consider rephrasing or even deleting the statement.

Author Response

Dear reviewer

Please see the attachment

 

Sincerely

Ao-Ho Hsieh

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

The authors correctly answered my questions and substantially improved the english text.

Back to TopTop